HCA Healthcare, Inc. HCA is navigating a more complex operating environment in which healthy demand is being offset by an unfavorable shift in its service and payer mix. The company’s volume trends remain solid, but the composition of that growth is becoming increasingly important to earnings.
Same-facility equivalent admissions increased 2.7% year over year in the second quarter of 2026, while emergency room visits rose 3.6%. Same-facility equivalent admissions among insured patients, excluding exchange plans, also grew 3.2% year over year, indicating that core demand remains healthy. In the second quarter, adjusted EPS advanced 11% year over year, supported by higher admissions, better expense performance and Medicaid supplemental payments.
However, inpatient and outpatient surgeries declined 2.3% and 3.4% year over year in the second quarter of 2026, respectively, as weaker elective demand weighed on procedure volumes. The more significant pressure is coming from HCA’s payer mix. Same-facility exchange-related equivalent admissions fell 15%, while uninsured equivalent admissions increased 15%, reflecting a near one-for-one migration of patients losing exchange coverage.
Against these pressures, HCA is leaning on its resiliency program to control costs through digital tools, global capabilities and workforce initiatives. The company expects these efforts to improve cost trends in the second half of 2026 and into 2027. Although HCA’s revised 2026 guidance reflects heavier exchange-related pressure, continued volume growth, cost discipline and network expansion could help it sustain earnings growth despite a changing service mix. Its planned investments should also broaden access points, with additional inpatient beds and outpatient facilities expected to expand capacity across growing markets.
How Are Peers Faring?
Some of HCA’s peers in the medical space are Tenet Healthcare Corporation THC and Community Health Systems, Inc. CYH.
Tenet is also facing payer-mix pressure while benefiting from higher-acuity care and strong expense control. In the second quarter of 2026, THC’s same-hospital admissions rose 2.3% year over year, despite surgeries slipping 0.7%. Hospital adjusted EBITDA jumped 22.3%, while its ambulatory business continued to provide another earnings-growth avenue.
Community Health Systems reported improving same-store demand in the second quarter of 2026, with admissions up 1.9% year over year and adjusted admissions rising 2.9%. However, unfavorable change in payer mix, divestitures and higher medical specialist fees weighed on CYH’s adjusted EBITDA despite better reimbursement rates and supplemental payments.
HCA’s Price Performance, Valuation & Estimates
Shares of HCA Healthcare have gained 5.2% over the past year compared with the industry’s growth of 15.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, HCA Healthcare trades at a forward price-to-earnings ratio of 13.95, below the industry average of 16.44. HCA carries a Value Score of A.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HCA Healthcare’s 2026 earnings is pegged at $29.42 per share, implying 4.3% growth from the year-ago period.
Image Source: Zacks Investment Research
HCA stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
HCA Healthcare, Inc. (HCA): Free Stock Analysis Report
Tenet Healthcare Corporation (THC): Free Stock Analysis Report
Community Health Systems, Inc. (CYH): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).